WO2022143010A1 - 一种吡哆醛在制备治疗卵巢癌的药物中的用途 - Google Patents

一种吡哆醛在制备治疗卵巢癌的药物中的用途 Download PDF

Info

Publication number
WO2022143010A1
WO2022143010A1 PCT/CN2021/135415 CN2021135415W WO2022143010A1 WO 2022143010 A1 WO2022143010 A1 WO 2022143010A1 CN 2021135415 W CN2021135415 W CN 2021135415W WO 2022143010 A1 WO2022143010 A1 WO 2022143010A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridoxal
ovarian cancer
preparation
pbs
well
Prior art date
Application number
PCT/CN2021/135415
Other languages
English (en)
French (fr)
Inventor
令狐华
李若男
詹诗杰
刘斌
Original Assignee
重庆医科大学附属第一医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 重庆医科大学附属第一医院 filed Critical 重庆医科大学附属第一医院
Priority to GB2219507.7A priority Critical patent/GB2611905A/en
Publication of WO2022143010A1 publication Critical patent/WO2022143010A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • the invention belongs to the technical fields of molecular biology and medicine, and particularly relates to the use of pyridoxal in preparing a medicine for treating ovarian cancer.
  • the phosphorylated form of pyridoxal (PLP) is currently considered to be the active form of vitamin B6 and can participate in catalytic reactions as a coenzyme of various enzymes, the inhibitory effect of vitamin B6 on malignant tumors is also generally considered to be the effect of PLP.
  • PLP phosphorylated form of pyridoxal
  • the present invention provides a use of pyridoxal in the preparation of a drug for the treatment of ovarian cancer.
  • the present invention is achieved by the use of pyridoxal in the preparation of a medicament for treating ovarian cancer.
  • the pyridoxal is prepared into any pharmaceutically acceptable preparation.
  • Another object of the present invention is to provide a use of pyridoxal in the preparation of a reagent for inhibiting the proliferation of ovarian cancer cells; the ovarian cancer cells are SKOV3, OVCAR3, 3AO or ES-2.
  • Another object of the present invention is to provide a method for verifying the use of pyridoxal in the preparation of a reagent for inhibiting the proliferation of ovarian cancer cells, and the method for verifying the use of pyridoxal in the preparation of a reagent for inhibiting the proliferation of ovarian cancer cells
  • Methods include:
  • Step 1 obtain pyridoxal, prepare it into a 50 mM working solution with PBS, and sterilize it with a 0.22 ⁇ m filter in the dark by suction filtration;
  • Step 2 use the xCELLigence workstation and the corresponding culture plate to perform label-free counting detection of living cells.
  • step 2 the use of the xCELLigence workstation and the corresponding culture plate to perform label-free counting and detection of living cells includes:
  • the present invention has confirmed through experiments that pyridoxal can inhibit the proliferation of ovarian cancer cells, and the inhibitory effect is very significant, so it can be used for the preparation of drugs for the treatment of ovarian cancer, Or prepare relevant reagents for studying the mechanism of ovarian cancer occurrence and development.
  • PL is one of the intermediate metabolites of vitamin B6, and vitamin B6 is a water-soluble vitamin, and its application safety is high. Therefore, PL has a strong clinical application possibility in the treatment of ovarian cancer.
  • the present invention detects and compares the effects of pyridoxal PL and its phosphate ester PLP on the proliferation ability of ovarian cancer cells by label-free counting of living cells.
  • the inhibitory effect of PL on ovarian cancer cells is significantly higher than that of PLP at the same concentration. Further research and development of new uses of PL will be beneficial to make full use of this compound and promote the treatment of clinically relevant diseases.
  • the present invention confirms through experiments that PL can inhibit the proliferation of ovarian cancer cells, so it can be used to prepare medicines for treating ovarian cancer, or prepare relevant reagents for studying the mechanism of occurrence and development of ovarian cancer. At the same time, the present invention proves that the inhibitory effect of pyridoxal on the proliferation of ovarian cancer cells is much more significant than that of other substances on the proliferation of ovarian cancer cells.
  • Fig. 1 is the flow chart of the method for verifying the purposes of pyridoxal in the preparation of the reagent that suppresses ovarian cancer cell proliferation provided by the embodiment of the present invention
  • FIG. 2 is a schematic diagram of the results of a label-free counting experiment of living cells provided by the embodiment of the present invention.
  • FIG. 3 is a schematic diagram of the growth of cell clones after the SKOV3 provided in the embodiment of the present invention is treated with PBS or 0.5mM PL for 6 days;
  • FIG. 4 is a schematic diagram of the growth of cell clones after the OVCAR3 provided in the embodiment of the present invention is treated with PBS or 0.5 mM PL for 6 days;
  • FIG. 5 is a schematic diagram of the growth of cell clones after 6 days of PBS or 0.5mM PL treatment of 3AO provided in the embodiment of the present invention
  • Figure 6 is a schematic diagram of the growth of cell clones after ES-2 provided in the embodiment of the present invention is treated with PBS or 0.5mM PL for 6 days.
  • the present invention provides a use of pyridoxal in the preparation of a medicament for treating ovarian cancer.
  • the present invention is described in detail below with reference to the accompanying drawings.
  • the pyridoxal provided in the embodiment of the present invention is an intermediate metabolite of vitamin B6, which is obtained from the oxidation of pyridoxine, and its chemical formula is: 3-hydroxy-5-hydroxymethyl-2-methylpyridine-4-carbaldehyde, molecular weight
  • the structural formula is:
  • ovarian cancer cells are SKOV3, OVCAR3, 3AO or ES-2.
  • the method for verifying the use of pyridoxal in the preparation of a reagent for inhibiting the proliferation of ovarian cancer cells includes the following steps:
  • step S102 the label-free counting detection of living cells using the xCELLigence workstation and the corresponding culture plate provided by the embodiment of the present invention includes:
  • PL and PLP were purchased from sigma company, prepared as 50 mM working solution using PBS, and sterilized by suction filtration with a 0.22 ⁇ m filter in the dark. Viable cell label-free counting (RTCA) was performed using the xCELLigence workstation and the corresponding culture plate (E-plate 96).
  • RTCA Viable cell label-free counting
  • PL and PLP can inhibit the proliferation of ovarian cancer cells, and the inhibitory ability of PL on the proliferation of ovarian cancer cells is significantly stronger than that of PLP at the same concentration.
  • the live cell label-free counting experiment showed that PL significantly inhibited the growth of ovarian cancer cell lines SKOV3, OVCAR3, 3AO and ES-2, and its inhibitory effect was significantly higher than that of PLP (**P ⁇ 0.01).
  • PL can be used to prepare drugs for the treatment of ovarian cancer, or to prepare relevant reagents for studying the mechanism of occurrence and development of ovarian cancer. And in the research process of the present invention, it is found that the inhibitory effect of PL on the proliferation of ovarian cancer cells is significantly better than some other compounds.
  • Figure 3 shows the growth of cell clones after SKOV3 was treated with PBS or 0.5mM PL for 6 days
  • Figure 4 shows the growth of cell clones after OVCAR3 was treated with PBS or 0.5mM PL for 6 days
  • Figure 5 shows the cell clones of 3AO treated with PBS or 0.5mM PL for 6 days Clonal growth
  • Figure 6 shows the growth of cell clones after ES-2 was treated with PBS or 0.5 mM PL for 6 days.
  • 0.5Mm PL significantly inhibited the clonogenic ability of the above three ovarian cancer cell lines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

吡哆醛在制备治疗卵巢癌的药物中的用途，吡哆醛制备成药学上接受的任何一种制剂。验证吡哆醛在制备治疗卵巢癌的药物中的用途的方法。吡哆醛在制备抑制卵巢癌细胞增殖的试剂中的用途，以及在制备研究卵巢癌发生发展机制的相关试剂中的用途。

Description

一种吡哆醛在制备治疗卵巢癌的药物中的用途
本申请要求于2020年12月28日提交中国专利局、申请号为202011577585.5、发明名称为“一种吡哆醛在制备治疗卵巢癌的药物中的用途”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明属于分子生物学和医药技术领域，尤其涉及一种吡哆醛在制备治疗卵巢癌的药物中的用途。
背景技术
目前，卵巢癌的死亡率稳居女性生殖系统恶性肿瘤之首，其疾病进展隐匿，预后差，严重威胁着女性健康。维生素B6的摄取被发现与降低恶性肿瘤的发生及改善预后有关，吡哆醛是维生素B6的主要代谢产物之一，有磷酸化形式(PLP)与非磷酸化形式(PL)两个类型。尽管目前磷酸化形式的吡哆醛(PLP)被认为是维生素B6的活性形式，可作为多种酶的辅酶参与催化反应，维生素B6对恶性肿瘤的抑制作用也通常被认为是PLP的作用。现有技术存在的问题及缺陷为：目前尚未见到关于非磷酸化形式的吡哆醛PL在肿瘤中的研究，但是非磷酸化形式的吡哆醛传统被认为是维生素B6的非活性形式，其功能尚未被认可。
发明内容
针对现有技术存在的问题，本发明提供了一种吡哆醛在制备治疗卵巢癌的药物中的用途，我们反复在卵巢癌细胞内对PLP与PL的抗癌效能进行验证，结果均提示相同浓度的PLP对卵巢癌细胞的抑制作用明显不如PL。
本发明是这样实现的，一种吡哆醛在制备治疗卵巢癌的药物中的用途。
进一步，所述吡哆醛制备成药学上接受的任何一种制剂。
本发明的另一目的在于提供一种吡哆醛在制备抑制卵巢癌细胞增殖的试剂中的用途；所述卵巢癌细胞为SKOV3、OVCAR3、3AO或ES-2。
本发明的另一目的在于提供一种验证所述吡哆醛在制备抑制卵巢癌细胞增殖的试剂中的用途的方法，所述验证吡哆醛在制备抑制卵巢癌细胞增殖的试剂中的用途的方法包括：
步骤一，获取吡哆醛，并利用PBS配制为50mM工作液，利用0.22μm滤器避光抽滤灭菌；
步骤二，利用xCELLigence工作站及对应的培养板进行活细胞无标记计数检测。
进一步，步骤二中，所述利用xCELLigence工作站及对应的培养板进行活细胞无标记计数检测包括：
向E-plate 96孔板中加入50μl完全培养基测定基线值，再向孔中加入混合均匀的SKOV3、OVCAR3悬液100μl，2μl吡哆醛，并用完全培养基补足至孔内液体为200μl，令吡哆醛工作浓度达0.5mM，对照组用等量PBS处理；室温放置30min后，设置自动扫描间隙为15min，检测细胞增殖曲线，总扫描时间为72小时。
结合上述的所有技术方案，本发明所具备的优点及积极效果为：本发明通过实验证实了吡哆醛可抑制卵巢癌细胞增殖，且抑制作用十分显著，因此可用于制备治疗卵巢癌的药物，或制备研究卵巢癌发生发展机制的相关试剂。PL是维生素B6中间代谢产物之一，而维生素B6是水溶性维生素，其应用安全性较高，因此PL在治疗卵巢癌方面具有很强的临床应用可能。
本发明通过活细胞无标记计数检测并比较了吡哆醛PL与其磷酸酯形式的PLP对卵巢癌细胞增殖能力的影响，相同浓度下PL对卵巢癌细胞的抑制效应显著高于PLP。而进一步研究和开发PL的新用途将有益于充分利用该种化合物，促进临床相关疾病的治疗。
本发明通过实验证实了PL可抑制卵巢癌细胞增殖，因此可用于制备治疗卵巢癌的药物，或制备研究卵巢癌发生发展机制的相关试剂。同时本发明证明吡哆醛对于卵巢癌细胞增殖的抑制作用相比于其他物质对于卵巢癌细胞增殖的抑制作用要显著得多。
附图说明
为了更清楚地说明本申请实施例的技术方案，下面将对本申请实施例中所需要使用的附图做简单的介绍，显而易见地，下面所描述的附图仅仅是本申请的一些实施例，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下还可以根据这些附图获得其他的附图。
图1是本发明实施例提供的验证吡哆醛在制备抑制卵巢癌细胞增殖 的试剂中的用途的方法的流程图；
图2是本发明实施例提供的活细胞无标记计数实验结果示意图；
图3是本发明实施例提供的SKOV3经PBS或0.5mM PL处理6天后细胞克隆生长情况示意图；
图4是本发明实施例提供的OVCAR3经PBS或0.5mM PL处理6天后细胞克隆生长情况示意图；
图5是本发明实施例提供的3AO经PBS或0.5mM PL处理6天后细胞克隆生长情况示意图；
图6是本发明实施例提供的ES-2经PBS或0.5mM PL处理6天后细胞克隆生长情况示意图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅仅用以解释本发明，并不用于限定本发明。
针对现有技术存在的问题，本发明提供了一种吡哆醛在制备治疗卵巢癌的药物中的用途，下面结合附图对本发明作详细的描述。
本发明实施例提供的吡哆醛是维生素B6的中间代谢产物，由吡哆醇氧化而来，其化学式为：3-羟基-5-羟甲基-2-甲基吡啶-4-甲醛，分子结构式为：
Figure PCTCN2021135415-appb-000001
本发明实施例提供的吡哆醛在制备治疗卵巢癌的药物中的用途。
本发明实施例提供的吡哆醛制备抑制卵巢癌细胞增殖的试剂中的用途；所述卵巢癌细胞为SKOV3、OVCAR3、3AO或ES-2。
如图1所示，本发明实施例提供的验证吡哆醛在制备抑制卵巢癌细胞增殖的试剂中的用途的方法包括以下步骤：
S101，获取吡哆醛，并利用PBS配制为50mM工作液，利用0.22μm滤 器避光抽滤灭菌；
S102，利用xCELLigence工作站及对应的培养板进行活细胞无标记计数检测。
步骤S102中，本发明实施例提供的利用xCELLigence工作站及对应的培养板进行活细胞无标记计数检测包括：
向E-plate 96孔板中加入50μl完全培养基测定基线值，再向孔中加入混合均匀的SKOV3、OVCAR3、3AO、ES-2悬液100μl，2μl吡哆醛，并用完全培养基补足至孔内液体为200μl，令吡哆醛工作浓度达0.5mM，对照组用等量PBS处理；室温放置30min后，设置自动扫描间隙为15min，检测细胞增殖曲线(图2)，总扫描时间为72小时。
下面结合具体实施例对本发明的技术效果作进一步描述。
实施例1：
1、PL、PLP购自sigma公司，使用PBS配制为50mM工作液，0.22μm滤器避光抽滤灭菌。使用xCELLigence工作站及对应的培养板(E-plate 96)进行活细胞无标记计数(RTCA)检测。
2、PL、PLP可以抑制卵巢癌细胞的增殖，且PL对卵巢癌细胞增殖的抑制能力显著强于同等浓度PLP。
向E-plate 96孔板中加入50μl完全培养基测定基线值，再向孔中加入混合均匀的SKOV3、OVCAR3、3AO、ES-2悬液100μl(1×10 5个/ml)，2μl PL或PLP，并用完全培养基补足至孔内液体为200μl，使PL及PLP工作浓度达0.5mM，对照组用等量PBS处理。室温放置30min后，设置自动扫描间隙为15min，检测细胞增殖曲线，总扫描时间为72小时。参见图2，活细胞无标记计数实验显示PL明显抑制卵巢癌细胞株SKOV3、OVCAR3、3AO和ES-2的生长，且其抑制效应显著高于PLP(**P<0.01)。
以上结果提示PL可用于制备治疗卵巢癌的药物，或制备研究卵巢癌发生发展机制的相关试剂。且本发明在研究过程中发现PL对于卵巢癌细胞增殖的抑制作用要显著优于其他一些化合物。
下面结合实验对本发明的技术效果作详细的描述。
本实验向24孔板每孔中加入500个卵巢癌SKOV3、OVCAR3、3AO、ES-2细胞及500μl完全培养基，再向孔中加入PL或等体积PBS，使PL终浓 度为0.5mM。置于37℃孵箱中培养6天后，4％多聚甲醛固定细胞，结晶紫染色后观察细胞克隆形成数目及大小(图3-图5)。
图3为SKOV3经PBS或0.5mM PL处理6天后细胞克隆生长情况；图4为OVCAR3经PBS或0.5mM PL处理6天后细胞克隆生长情况；图5为3AO经PBS或0.5mM PL处理6天后细胞克隆生长情况；图6为ES-2经PBS或0.5mM PL处理6天后细胞克隆生长情况。0.5Mm PL显著抑制了以上三种卵巢癌细胞系克隆形成的能力。
以上所述，仅为本发明的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等，都应涵盖在本发明的保护范围之内。

Claims (12)

  1. 一种吡哆醛在制备治疗卵巢癌的药物中的用途。
  2. 如权利要求1所述吡哆醛在制备治疗卵巢癌的药物中的用途，其特征在于，所述吡哆醛制备成药学上接受的任何一种制剂。
  3. 一种吡哆醛在制备抑制卵巢癌细胞增殖的试剂中的用途。
  4. 如权利要求3所述吡哆醛在制备抑制卵巢癌细胞增殖的试剂中的用途，其特征在于，所述卵巢癌细胞为SKOV3、OVCAR3、3AO或ES-2。
  5. 一种验证如权利要求3或4所述用途的方法，其特征在于，所述验证吡哆醛在制备抑制卵巢癌细胞增殖的试剂中的用途的方法包括：
    步骤一，获取吡哆醛，并利用PBS配制为工作液，利用滤器避光抽滤灭菌；
    步骤二，利用xCELLigence工作站及对应的培养板进行活细胞无标记计数检测。
  6. 如权利要求5所述方法，其特征在于，步骤一，获取吡哆醛，并利用PBS配制为50mM工作液，利用0.22μm滤器避光抽滤灭菌。
  7. 如权利要求5所述方法，其特征在于，步骤二中向E-plate 96孔板中加入完全培养基测定基线值，再向孔中加入混合均匀的SKOV3、OVCAR3、3AO或ES-2悬液，吡哆醛，并用完全培养基补足孔内液体，对照组用等量PBS处理；室温放置后，设置自动扫描间隙，检测细胞增殖曲线。
  8. 如权利要求7所述方法，其特征在于，向E-plate 96孔板中加入50μl完全培养基测定基线值，再向孔中加入混合均匀的SKOV3、OVCAR3、3AO或ES-2悬液100μl，2μl吡哆醛，并用完全培养基补足至孔内液体为200μl。
  9. 如权利要求7所述方法，其特征在于，吡哆醛工作浓度达0.5mM，对照组用等量PBS处理。
  10. 如权利要求7所述方法，其特征在于，室温放置30min后，设置自动扫描间隙为15min，检测细胞增殖曲线，总扫描时间为72小时。
  11. 一种治疗卵巢癌的药物，其特征在于，所述药物以吡哆醛为有效成分。
  12. 吡哆醛在制备研究卵巢癌发生发展机制的相关试剂中的用途。
PCT/CN2021/135415 2020-12-28 2021-12-03 一种吡哆醛在制备治疗卵巢癌的药物中的用途 WO2022143010A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2219507.7A GB2611905A (en) 2020-12-28 2021-12-03 Use of pyridoxal in preparation of drugs for treating ovarian cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011577585.5 2020-12-28
CN202011577585.5A CN112691103B (zh) 2020-12-28 2020-12-28 一种吡哆醛在制备治疗卵巢癌的药物中的用途

Publications (1)

Publication Number Publication Date
WO2022143010A1 true WO2022143010A1 (zh) 2022-07-07

Family

ID=75512203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/135415 WO2022143010A1 (zh) 2020-12-28 2021-12-03 一种吡哆醛在制备治疗卵巢癌的药物中的用途

Country Status (3)

Country Link
CN (1) CN112691103B (zh)
GB (1) GB2611905A (zh)
WO (1) WO2022143010A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112691103B (zh) * 2020-12-28 2022-07-26 重庆医科大学附属第一医院 一种吡哆醛在制备治疗卵巢癌的药物中的用途
CN115531380A (zh) * 2022-09-19 2022-12-30 重庆医科大学附属第一医院 一种氟代吡哆醛在制备用于抗癌症的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1537532A (zh) * 2003-04-18 2004-10-20 方 谢 吡哆辛及其衍生物在制备药物中的用途
CN106727620A (zh) * 2016-12-01 2017-05-31 复旦大学附属金山医院 磷酸吡哆醛在制备治疗卵巢癌的药物中的应用
CN112691103A (zh) * 2020-12-28 2021-04-23 重庆医科大学附属第一医院 一种吡哆醛在制备治疗卵巢癌的药物中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2536719A1 (en) * 2010-02-19 2012-12-26 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents
CN104922697B (zh) * 2015-05-26 2018-02-27 复旦大学附属金山医院 降低磷酸吡哆醇氧化酶治疗卵巢癌

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1537532A (zh) * 2003-04-18 2004-10-20 方 谢 吡哆辛及其衍生物在制备药物中的用途
CN106727620A (zh) * 2016-12-01 2017-05-31 复旦大学附属金山医院 磷酸吡哆醛在制备治疗卵巢癌的药物中的应用
CN112691103A (zh) * 2020-12-28 2021-04-23 重庆医科大学附属第一医院 一种吡哆醛在制备治疗卵巢癌的药物中的用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHENG LIJUAN;ZHAN SHIJIE;LIU BIN;LINGHU HUA: "Alkaline phosphatase,liver/bone/kidney,inhibits proliferation of ovarian cancer cell line SKOV3", JOURNAL OF THIRD MILITARY MEDICAL UNIVERSITY, vol. 40, no. 1, 8 November 2017 (2017-11-08), pages 58 - 63, XP055948987, ISSN: 1000-5404, DOI: 10.16016/j.1000-5404.201708130 *
GALLUZZI LORENZO, VITALE ILIO, SENOVILLA LAURA, OLAUSSEN KEN ANDRÉ, PINNA GUILLAUME, EISENBERG TOBIAS, GOUBAR AÏCHA, MARTINS ISABE: "Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer", CELL REPORTS, vol. 2, no. 2, 1 August 2012 (2012-08-01), US , pages 257 - 269, XP055948990, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2012.06.017 *
LI LING: "The Study of Antitumor Activity and Mechanism of Rasfonin", CHINESE DOCTORAL DISSERTATIONS FULL-TEXT DATABASE, no. 11, 20 June 2013 (2013-06-20), pages 1 - 102, XP055948973, ISSN: 1674-022X *
LUO MU: "ALPL Reduces the Potential of Migration and Invasion in High Grade Serous Ovarian Cancer via Down-regulating a FZD2/STAT3 Signaling Pathway", CHINESE MASTER'S THESES FULL-TEXT DATABASE, no. 1, 1 May 2020 (2020-05-01), pages 1 - 42, XP055948964, ISSN: 1674-0246 *
MONIQUE P. REBOE; TERRY-ANN WAITE; ARKENE S. LEVY; SIVANESAN DHANDAYUTHAPANI; APPU RATHINAVELU: "Abstract 1751: Y15 and Pyridoxal 5′ Phosphate enhances the cytotoxic profile of Cisplatin and Paclitaxel in platinum resistant ovarian cancer cells", CANCER RESEARCH, vol. 75, no. 15, Suppl, 31 August 2015 (2015-08-31), US , pages 1751, XP009538059, ISSN: 1538-7445, DOI: 10.1158/1538-7445.AM2015-1751 *
TAN WEI;LIU BIN;LING HUHUA: "Pyridoxal Kinase (Pdxk) Promotes the Proliferation of Serous Ovarian Cancer Cells and Is Associated With Poor Prognosis", CHINESE JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 36, no. 6, 30 June 2020 (2020-06-30), pages 542 - 548, XP055948989, ISSN: 1007-8738, DOI: 10.13423/j.cnki.cjcmi.008989 *
ZHANG LINGYUN, ZHOU DAIBING, GUAN WENCAI, REN WEIMIN, SUN WENWEN, SHI JIMIN, LIN QUNBO, ZHANG JINGUO, QIAO TIANKUI, YE YULONG, WU : "Pyridoxine 5′-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer", CELL DEATH & DISEASE, vol. 8, no. 12, 1 January 2017 (2017-01-01), pages 1 - 18, XP055948981, DOI: 10.1038/s41419-017-0050-3 *

Also Published As

Publication number Publication date
CN112691103A (zh) 2021-04-23
GB202219507D0 (en) 2023-02-08
GB2611905A (en) 2023-04-19
CN112691103B (zh) 2022-07-26

Similar Documents

Publication Publication Date Title
WO2022143010A1 (zh) 一种吡哆醛在制备治疗卵巢癌的药物中的用途
CN108060132A (zh) 一种基于肿瘤细胞与肿瘤相关成纤维细胞的3d共培养模型
US20190307794A1 (en) Method for inducing transdifferentiation of immune cells based on exosomes
Tsering et al. Triphala suppresses growth and migration of human gastric carcinoma cells in vitro and in a zebrafish xenograft model
CN106943432A (zh) 一种脐带间充质干细胞来源的外泌体及其在制备治疗肝癌药物中的应用
CN114028573B (zh) 拟杆菌属肠道菌及其代谢相关物质在制备逆转氟尿嘧啶类药物耐药性的药物中的用途
WO2024060834A1 (zh) 一种氟代吡哆醛在制备用于抗癌症的药物中的用途
CN107569485A (zh) 一种治疗braf抑制剂耐药型黑色素瘤的复方制剂
Chang et al. From Hair to Colon: Hair Follicle‐Derived MSCs Alleviate Pyroptosis in DSS‐Induced Ulcerative Colitis by Releasing Exosomes in a Paracrine Manner
CN106389437A (zh) 低剂量西地那非作为抗肿瘤药物的应用
CN109985229B (zh) 化合物ilamycin C及其同系物在制备治疗三阴乳腺癌药物中的应用
CN107708728A (zh) 一种用于治疗胃癌的肿瘤疫苗及其制备方法
CN109260194A (zh) 白花前胡甲素在缓解抗肿瘤药物顺铂所致肾毒性中的应用
CN115887455B (zh) 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用
CN106974903A (zh) 洛铂在制备治疗恶性滋养细胞肿瘤药物中的应用
CN112245587A (zh) 含nad和胆碱酯酶抑制剂的药物组合物及其用途
CN111514133A (zh) 木香烃内酯和/或去氢木香内酯在制备治疗黑色素瘤的药品中的应用
CN114366740B (zh) 化合物a-6在制备广谱抗癌药物中的应用
CN108823167A (zh) 一种增强特罗凯药效的方法
CN111588710B (zh) 一种针对egfr耐药突变c797s的联用药物及用途
CN114224893B (zh) 喹唑啉衍生物在制备防治砷致肝损伤药物中的用途
CN114028407A (zh) 一种醉茄素a在制备抗肿瘤药物中的应用
Dong et al. Curcumin Nanoparticles Inhibit Liver Cancer by Inhibiting Angiogenesis
CN115737645A (zh) At56联合索拉非尼在外周t细胞淋巴瘤中的应用
Shen et al. Trifluoperazine activates AMPK/mTOR/ULK1 signaling pathway to induce mitophagy in osteosarcoma cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21913751

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 202219507

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20211203

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21913751

Country of ref document: EP

Kind code of ref document: A1